June 26, 2019 06:59 AM EDTUpdated July 3, 07:24 AM

While Akorn works to revive its fortunes, the FDA hits it with another warning letter

Akorn just can’t dig itself out of its hole.

The specialty generic drugmaker has received yet another warning letter from the FDA this year. Without …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

While Ako­rn works to re­vive its for­tunes, the FDA hits it with an­oth­er warn­ing let­ter